|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10076555||CLIVUNEL INC||Methods of inducing melanogenesis in a subject|| |
(1 year, 4 months from now)
|US8334265||CLIVUNEL INC||Method of treatment of photodermatoses|| |
(5 years from now)
Scenesse is owned by Clivunel Inc.
Scenesse contains Afamelanotide.
Scenesse has a total of 2 drug patents out of which 0 drug patents have expired.
Scenesse was authorised for market use on 08 October, 2019.
Scenesse is available in implant;subcutaneous dosage forms.
Scenesse can be used as increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp).
Drug patent challenges can be filed against Scenesse from 2023-10-09.
The generics of Scenesse are possible to be released after 11 March, 2029.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||Oct 8, 2026|
|New Chemical Entity Exclusivity (NCE)||Oct 8, 2024|
NCE-1 date: 2023-10-09
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic